Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05287971
Other study ID # PERCUSSION
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date August 1, 2023
Est. completion date May 1, 2025

Study information

Verified date August 2023
Source Maastricht Radiation Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Offering an early-initiated supportive care program to stage III NSCLC patients to prevent deterioration of performance status and increase compliance of patients that complete chemoradiation as well as the patients receiving 12 months of durvalumab.


Description:

In inoperable Stage III Non-Small Cell Lung Cancer (NSCLC), consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab, given within 6 weeks after completion of concurrent platinum-based chemoradiotherapy (CCRT) for 12 months results in remarkable improvement of 3-year overall survival rates (57% vs 43.5%). This tri-modal therapy has become the new standard of care. Unfortunately, the tri-modal therapy frequently causes adverse events such as fatigue and, to a much lesser degree, cough, dyspnea and pneumonitis, resulting in treatment cessation in 15% - 53% of the patients (15%) (53%). For the most optimal overall survival (OS) and disease-free survival (DFS), compliance to the full treatment regimen, i.e. in the ideal situation 100% of patients completing their full course of CCRT and receiving durvalumab for one year, is expected to have significant and relevant beneficial effects. Optimizing patients' fitness is essential in order to handle the tough full treatment regimen.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 1, 2025
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathological diagnosis of adequately staged (according to standard practice using chest-CT, FDG-PET, brain imaging MRI/CT) NSCLC - Participant is willing and able to give informed consent for participation in the trial - Aged 18 years or above - Scheduled to receive one of the following two therapeutic strategies: - Concurrent chemotherapy and radiotherapy with photons (60 Gy in 30 fractions of 2 Gy) followed by durvalumab in patients with stage III NSCLC - Concurrent chemotherapy and radiotherapy with protons (60 Gy in 30 fractions of 2 Gy) followed by durvalumab in patients with stage III NSCLC - Able and willing to comply with all trial requirements Exclusion Criteria: - Mixed non-small cell lung cancer with other histology such as small cell lung cancer - Not able to comply with the study protocol - Less than 18 years old - Pregnancy or not able to comply with adequate contraception in women with child baring potential - Previous radiotherapy to the chest for benign or malignant conditions, including radiation for breast cancer - Previous malignancy treated with chemotherapy, immune therapy or radiotherapy (irrespective of when this happened) - Previous malignancies treated with surgery only are allowed if 2 years or more before inclusion in the present study

Study Design


Intervention

Behavioral:
Lifestyle advice
Patients will receive lifestyle advice regarding nutricion and exercise and will be monitored with regard to exercise and vital signs.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Maastricht Radiation Oncology

Outcome

Type Measure Description Time frame Safety issue
Primary Compliance Compliance to CCRT and durvalumab treatment 12 months
Secondary Percentage adhering advice Improving standard of care lifestyle support by measuring % patients successfully adhering to the dietary, exercise, smoking advice 12 months
Secondary Perctenage use of watch Improving standard of care lifestyle support by measuring % use of the watch (and app) 12 months
Secondary Percentage dysphagia Improving standard of care lifestyle support by measuring % grade 3 dysphagia and odynophagia 12 months
Secondary Percentage dyspnea Improving standard of care lifestyle support by measuring % grade 2 dyspnea 12 months
Secondary Percentage hospitalization Improving standard of care lifestyle support by measuring % hospitalization for (treatment-related) complications + specification (from start until 6 weeks after radiotherapy) 12 months
Secondary Standard of care lifestyle support Measuring match between lifestyle advice and personal circumstances by questionnaire 12 months
Secondary Barriers Measuring adherence of barriers and facilitators in lifestyle support by questionnaire 12 months
Secondary Proton/photon Improving standard of care lifestyle support by measuring the difference between proton and photon therapy i the above mentioned outcome 12 months
Secondary Durvalumab Improving standard of care lifestyle support by measuring % patients receiving durvalumab 12 months
Secondary Quality of life questionnaire Improving standard of care lifestyle support by measuring the quality of life by EORTC QLQ-C30/-LC13 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1